Case report and novel treatment of an autosomal recessive Leigh syndrome caused by short‐chain enoyl‐CoA hydratase deficiency. Issue 5 (7th March 2019)

• Record Type: Journal Article
• Authors: Shayota, Brian J.; Soler‐Alfonso, Claudia; Bekheirnia, Mir Reza; Mizerik, Elizabeth; Boyer, Suzy W.; Xiao, Rui; Yang, Yaping; Elsea, Sarah H.; Scaglia, Fernando
• Is Part Of: American journal of medical genetics. Volume 179:Issue 5(2019)
• Page Start: 803
• Page End: 807
• Publication Date: 2019-03-07
• Subjects: crotonase -- inborn error of metabolism -- Leigh syndrome -- valine metabolism; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.61074
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract : Short chain enoyl‐CoA hydratase (SCEH) deficiency leads to a severe form of autosomal recessive Leigh syndrome with inevitable neurological decline and early mortality. SCEH is most notably involved in valine catabolism, a deficiency of which results in various metabolic alterations, including increased levels of the highly reactive metabolite 2‐methacrylyl‐CoA. With no proven treatments available to date, it has been speculated that patients may respond to a valine restricted diet and/or N ‐acetylcysteine supplementation, as suggested by early studies of a very similar inborn error of metabolism, 3‐hydroxyisobutyryl‐CoA hydrolase deficiency. We describe a patient with typical Leigh syndrome clinical findings and identified compound heterozygous variants in ECSH1 . Valine‐restricted diet was initiated at 6 months of age and N ‐acetylcysteine supplementation at 9 months with subsequent improvement in growth and slow progress in developmental milestones. However, at 15 months, the patient aspirated during a breakthrough seizure from which he did not recover and died soon after from related complications. This report highlights some of the challenges that remain in the management and treatment of SCEH deficiency, while demonstrating that a valine restricted diet and N ‐acetylcysteine can be safely administered with the potential for clinical improvement.